Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
Novartis Pharma K.K. (?Novartis Pharma?) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients:
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail:?investor.relations@novartis.com
- Tabrecta? (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC),
- Entresto??(sacubitril valsartan sodium hydrate) in chronic heart failure,
- Mayzent??(siponimod fumaric acid) in secondary progressive MS,
- Enerzair??(glycopyrronium bromide, indacaterol acetate, mometasone furoate) and
- Atectura???(indacaterol acetate, mometasone furoate) in different forms of asthma
# # #
Novartis Media Relations E-mail:?media.relations@novartis.com
Satoshi Jean-Paul Sugimoto Director External Communications ? Europe/Asia +41 79 619 20 35 (mobile) | Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler Isabella Zinck | +41 61 324 8425 +41 61 324 7188 |